GlobeNewswire
Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product and Place, with Executive and Consultant Guides
📈
AI Sentiment
Highly Positive
9/10
- Home
- ILMN
ILMN
Illumina Inc.
as of 12-12-2025 3:55pm EST
$135.03
$1.41
-1.03%
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Chart Type:
Time Range:
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 18.9B | IPO Year: | 2000 |
| Target Price: | $114.93 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $68.70 - $153.06 | Next Earning Date: | 10-30-2025 |
| Revenue: | $4,288,000,000 | Revenue Growth: | -2.32% |
| Revenue Growth (this year): | -0.02% | Revenue Growth (next year): | 2.08% |
AI-Powered ILMN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 72.37%
72.37%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Illumina Inc. (ILMN)
Wedel Christensen Jakob
Sell
SVP, Strategy/Corp Development
ILMN Dec 8, 2025
Avg Cost/Share
$129.27
Shares
549
Total Value
$70,969.23
Owned After
10,952
SEC Form 4
Gottlieb Scott
Buy
Director
ILMN Nov 3, 2025
Avg Cost/Share
$122.13
Shares
500
Total Value
$61,065.00
Owned After
12,523
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Wedel Christensen Jakob | ILMN | SVP, Strategy/Corp Development | Dec 8, 2025 | Sell | $129.27 | 549 | $70,969.23 | 10,952 | |
| Gottlieb Scott | ILMN | Director | Nov 3, 2025 | Buy | $122.13 | 500 | $61,065.00 | 12,523 |
Latest Illumina Inc. News
ILMN Breaking Stock News: Dive into ILMN Ticker-Specific Updates for Smart Investing
GlobeNewswire
Patient Engagement in Genomics Research Fuels Growth in Healthcare Segment
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound
📊
AI Sentiment
Positive
6/10
Compare ILMN vs Leading Stocks
See how ILMN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ILMN Illumina Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.